Proteomic and clinical biomarkers for acute mountain sickness in a longitudinal cohort
Published in Communications Biology, 2022
Recommended citation: Yang, J., Jia, Z., Song, X. et al. Proteomic and clinical biomarkers for acute mountain sickness in a longitudinal cohort. Commun Biol 5, 548 (2022). https://doi.org/10.1038/s42003-022-03514-6 http://zhilongjia.github.io/files/2022_AMS_proteomic_biomarker.pdf
Ascending to high-altitude by non-high-altitude natives is a well-suited model for studying acclimatization to extreme environments. Acute mountain sickness (AMS) is frequently experienced by visitors. The diagnosis of AMS mainly depends on a self-questionnaire, revealing the need for reliable biomarkers for AMS. Here, we profiled 22 AMS symptom phenotypes, 65 clinical indexes, and plasma proteomic profiles of AMS via a combination of proximity extension assay and multiple reaction monitoring of a longitudinal cohort of 53 individuals. We quantified 1069 proteins and validated 102 proteins. Via differential analysis, machine learning, and functional association analyses. We found and validated that RET played an important role in the pathogenesis of AMS. With high-accuracies (AUCs > 0.9) of XGBoost-based models, we prioritized ADAM15, PHGDH, and TRAF2 as protective, predictive, and diagnostic biomarkers, respectively. Our findings shed light on the precision medicine for AMS and the understanding of acclimatization to high-altitude environments.
Preprint : https://www.medrxiv.org/content/10.1101/2021.10.18.21265176v1
Reproducible Study link: https://github.com/Monica1227/AMS_biomarker
Recommended citation: Yang, J., Jia, Z., Song, X. et al. Proteomic and clinical biomarkers for acute mountain sickness in a longitudinal cohort. Commun Biol 5, 548 (2022). https://doi.org/10.1038/s42003-022-03514-6.